- Clinical Trial of mRNA Universal Influenza Vaccine Candidate Begins
- https://www.niaid.nih.gov/news-events/clinical-trial-mrna-universal-influenza-vaccine-candidate-begins
- https://clinicaltrials.gov/ct2/show/NCT05755620
- Clinical trial, experimental universal influenza vaccine
- National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC),
- (part of National Institutes of Health)
- Enrolling volunteers, Duke University, Durham, North Carolina
- Phase 1 trial
- H1ssF-3928 mRNA-LNP, for safety and ability to induce an immune response.
- N = up to 50 healthy volunteers, (18 through 49)
- Three groups of 10 participants each
- 10, 25 and 50 micrograms
- After evaluation of the data to determine an optimum dosage,
- an additional 10 to receive the optimum dosage
- Study include a group, receive a current quadrivalent.
- Comparison between “immunogenicity and safety”
- Follow-up appointments for up to one year
- Annual seasonal flu vaccines
- Valuable tools in controlling the spread and severity of influenza
- Do not provide immunity against every flu strain.
- Each year is based on prediction
- Vaccine manufacturers then need time
- (dominant strains of the virus can change)
- An effective universal flu vaccine
- Acting NIAID Director Hugh Auchincloss
- Protecting its recipients against a wide variety of strains,
- ideally providing durable long-term immunity.
- “A universal influenza vaccine would be a major public health achievement and could eliminate the need for both annual development of seasonal influenza vaccines, as well as the need for patients to get a flu shot each year”
- Defence against the spread of a future flu pandemic.
- Both vaccines use a specific portion of a flu protein,
- Hemagglutinin (HA) stern (not head) flu protein
- UK cements 10-year-partnership with Moderna in major boost for vaccines and research
- https://www.gov.uk/government/news/uk-cements-10-year-partnership-with-moderna-in-major-boost-for-vaccines-and-research
- to produce up to 250 million vaccines per year
- https://www.theguardian.com/business/2022/jun/22/moderna-build-uk-mrna-vaccine-research-manufacturing-centre-covid
- £1bn deal with the UK government
- UK government has committed to buying Moderna’s vaccines for the next decade.
- Harwell, Oxfordshire
- https://www.bbc.co.uk/news/uk-england-oxfordshire-64856379
- Innovation and Technology Centre built by the 2025
- Moderna
- provide the UK public with access to mRNA vaccines for a wide range of respiratory diseases
- Questions
- Control of antigen dose?
- How long antigen will be produced for?
- Degree of systemic distribution?
- Degree of systemic inflammation?
Show more